Cinical Trials Detail Page - Genesis HealthCare System - Zanesville, Ohio

Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients

Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients



Double Blind, Placebo-Controlled

Curcumin/placebo 2.0g three times daily by mouthfor duration of RT and one week post-RT

Standard RT(≥50Gy;1.8-2.0 Gyper session; 25-35 sessions)

Questionnaires: Weekly (at session 5):measure skin toxicity, Photograph IR, symptom Inventory, Pain Survey, skindex-29 wk 1, wk 3, End of RT, 1wk post RT, 1 month Post RT


  1. Female, diagnosis of non-infammatory breast adenocarcinoma and be referred for post-operative radioation therapy without cuoncurrent chemotherapy
  2. Adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment (Note: surgery is not required for eligibility).
  3. Breast reconstruction patients are eligible  (i.e., patients with implants or expanders while undergoing their radiation therapy).
  4. In-situ breast cancer patients are eligible.
  5. Bilateral breast cancer patients are eligible.
  6. Must be scheduled to receive 25-35 radiation treatment sesions (1 session per day) using standard irradation fractionation (1.8-2.0 Gy per session).
  7. Concurrent hormone treatment with radiation treatment allowed.
  8. Patients taking Herceptin® (Trastuzumab) are eligible.
  9. 21 years of age.
  10. Must not be pregnant.
IRB Protocol Number
URCC 10054
Principal Investigator(s)
J. Phillip Kuebler

Clinical Trial Categories

  • Cancer
Columbus Community Clinical Oncology Program
RN. Wendy Long, RN at 740-586-6618